Perspective Therapeutics Inc (CATX)

Currency in USD
3.8850
-0.0050(-0.13%)
Real-time Data·
CATX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 3 days
Fair Value
Day's Range
3.83003.9300
52 wk Range
1.600016.5500
Key Statistics
Prev. Close
3.89
Open
3.84
Day's Range
3.83-3.93
52 wk Range
1.6-16.55
Volume
194.5K
Average Volume (3m)
1.17M
1-Year Change
-68.35%
Book Value / Share
3.84
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CATX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.1071
Upside
+263.12%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Perspective Therapeutics Inc Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Perspective Therapeutics Inc SWOT Analysis


Radiopharmaceutical Pionee
Perspective Therapeutics leads in targeted cancer therapies with its innovative lead-specific chelator technology and diverse pipeline, positioning itself as a key player in the RPT space.
Clinical Progress
Explore the company's advancing VMT-α-NET program, with expanded patient enrollment and promising initial safety profiles, signaling confidence in its therapeutic potential.
Financial Outlook
Analysts maintain a strong buy consensus with an average price target of $16, balancing short-term caution against long-term optimism for CATX's platform and pipeline.
Strategic Advantages
Delve into CATX's decentralized manufacturing strategy and robust patent estate, potentially offering improved efficiency and a competitive edge in commercialization.
Read full SWOT analysis

Compare CATX to Peers and Sector

Metrics to compare
CATX
Peers
Sector
Relationship
P/E Ratio
−3.4x−1.9x−0.5x
PEG Ratio
−0.11−0.110.00
Price/Book
1.0x2.1x2.6x
Price / LTM Sales
194.8x10.3x3.3x
Upside (Analyst Target)
285.6%277.4%43.5%
Fair Value Upside
Unlock15.5%6.3%Unlock

Analyst Ratings

13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.1071
(+263.12% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.25 / -0.31
Revenue / Forecast
342.00K / 134.48K
EPS Revisions
Last 90 days

CATX Income Statement

People Also Watch

2.67
INMB
-6.48%
20.82
URGN
+4.70%
1.775
IPA
-3.01%
5.91
FDMT
+12.79%
21.38
VERA
+4.55%

FAQ

What Stock Exchange Does Perspective Therapeutics Trade On?

Perspective Therapeutics is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Perspective Therapeutics?

The stock symbol for Perspective Therapeutics is "CATX."

What Is the Perspective Therapeutics Market Cap?

As of today, Perspective Therapeutics market cap is 288.75M.

What Is Perspective Therapeutics's Earnings Per Share (TTM)?

The Perspective Therapeutics EPS (TTM) is -1.21.

When Is the Next Perspective Therapeutics Earnings Date?

Perspective Therapeutics will release its next earnings report on 07 Aug 2025.

From a Technical Analysis Perspective, Is CATX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Perspective Therapeutics Stock Split?

Perspective Therapeutics has split 1 times.

How Many Employees Does Perspective Therapeutics Have?

Perspective Therapeutics has 139 employees.

What is the current trading status of Perspective Therapeutics (CATX)?

As of 05 Aug 2025, Perspective Therapeutics (CATX) is trading at a price of 3.89, with a previous close of 3.89. The stock has fluctuated within a day range of 3.83 to 3.93, while its 52-week range spans from 1.60 to 16.55.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.